Dataset from An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00007110
下载链接
链接失效反馈官方服务：
资源简介：
This study will include participants with previously treated systemic relapsed or refractory
light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the
safety profile and the maximum tolerated dose/recommended phase 2 dose of MLN9078 (Ixazomib)
administered orally.
创建时间：
2025-10-01
